Loading
A phase 3 trial of Zoldonrasib, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC is a phase 3 interventional study registered as NCT07777822 by Revolution Medicines, Inc., with 430 participants planned, started 2026-08-14 and due to reach its primary completion in 2029-10. Interventions recorded: zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin. Conditions listed: NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Shares Revolution Medicines, Pemetrexed, Cisplatin, Carboplatin.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Shares Zoldonrasib, Revolution Medicines, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/